Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Insights and Advances in the Surgical Management of Hepatocellular Carcinoma
share announcement

Insights and Advances in the Surgical Management of Hepatocellular Carcinoma

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 4313

Special Issue Editors

Dr. Joseph DiNorcia

E-Mail Website
Guest Editor
Recanati/Miller Transplantation Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
Interests: liver resection and transplantation; living-donor liver transplantation; pediatric liver transplantation; hepatobiliary and pancreatic malignancies
Dr. Ganesh Gunasekaran

E-Mail Website
Guest Editor
1. Department of Surgery, Section of Hepatobiliary Surgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
2. Department of Surgery, Mount Sinai South Nassau, Oceanside, NY 11570, USA
Interests: hepatocellular carcinoma

Special Issue Information

Dear Colleagues,

As one of the most common cancers, hepatocellular carcinoma remains a global health challenge. Treatment for the hepatitis C virus, the obesity epidemic, and the rise of alcoholism from repercussions of the COVID-19 pandemic have shifted the etiologies of underlying liver diseases across the world. Additionally, the recognition of liver cancer associated with cardiac cirrhosis after the repair of congenital cardiac anomalies has introduced a new group of adult and pediatric patients at risk of developing hepatocellular carcinoma. In this changing landscape, there has been inspirational collaboration among surgeons, hepatologists, oncologists, radiologists, and scientists to create multidisciplinary approaches to these complicated patients.

Significant insights and advances continue to shape both liver resection and liver transplantation for hepatocellular carcinoma. For this Special Issue, we welcome original research and review papers that address recent developments in the surgical management of hepatocellular carcinoma. Minimally invasive and staged approaches to liver resection, and the use of living donation and machine perfusion to expand the donor pool for liver transplantation are ready for exploration. We are particularly interested in multidisciplinary treatment approaches that incorporate the latest strategies in tumor profiling, locoregional treatment, and systemic or immunotherapy to bridge patients to liver resection or liver transplantation. We welcome other novel surgical approaches to hepatocellular carcinoma as well.

We look forward to receiving your contributions.

Dr. Joseph DiNorcia
Dr. Ganesh Gunasekaran
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • hepatocellular carcinoma
  • surgical resection
  • liver transplantation
  • locoregional treatment
  • immunotherapy

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

14 pages, 241 KiB  
Article
Imaging Delay Following Liver-Directed Therapy Increases Progression Risk in Early- to Intermediate-Stage Hepatocellular Carcinoma
by Jordin Stanneart, Kelley G. Nunez, Tyler Sandow, Juan Gimenez, Daniel Fort, Mina Hibino, Ari J. Cohen and Paul T. Thevenot
Cancers 2024, 16(1), 212; https://doi.org/10.3390/cancers16010212 - 2 Jan 2024
Viewed by 1043
Abstract
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Patients with early-stage HCC are treated with liver-directed therapies to bridge or downstage for liver transplantation (LT). In this study, the impact of HCC care delay on HCC [...] Read more.
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related deaths in the world. Patients with early-stage HCC are treated with liver-directed therapies to bridge or downstage for liver transplantation (LT). In this study, the impact of HCC care delay on HCC progression among early-stage patients was investigated. Early-stage HCC patients undergoing their first cycle of liver-directed therapy (LDT) for bridge/downstaging to LT between 04/2016 and 04/2022 were retrospectively analyzed. Baseline variables were analyzed for risk of disease progression and time to progression (TTP). HCC care delay was determined by the number of rescheduled appointments related to HCC care. The study cohort consisted of 316 patients who received first-cycle LDT. The HCC care no-show rate was associated with TTP (p = 0.004), while the overall no-show rate was not (p = 0.242). The HCC care no-show rate and HCC care delay were further expanded as no-show rates and rescheduled appointments for imaging, laboratory, and office visits, respectively. More than 60% of patients experienced HCC care delay for imaging and laboratory appointments compared to just 8% for office visits. Multivariate analysis revealed that HCC-specific no-show rates and HCC care delay for imaging (p < 0.001) were both independently associated with TTP, highlighting the importance of minimizing delays in early-stage HCC imaging surveillance to reduce disease progression risk. Full article
(This article belongs to the Special Issue Insights and Advances in the Surgical Management of Hepatocellular Carcinoma)
27 pages, 3289 KiB  
Article
Improved Survival Outcomes with Surgical Resection Compared to Ablative Therapy in Early-Stage HCC: A Large, Real-World, Propensity-Matched, Multi-Centre, Australian Cohort Study
by Jonathan Abdelmalak, Simone I. Strasser, Natalie Ngu, Claude Dennis, Marie Sinclair, Avik Majumdar, Kate Collins, Katherine Bateman, Anouk Dev, Joshua H. Abasszade, Zina Valaydon, Daniel Saitta, Kathryn Gazelakis, Susan Byers, Jacinta Holmes, Alexander J. Thompson, Dhivya Pandiaraja, Steven Bollipo, Suresh Sharma, Merlyn Joseph, Amanda Nicoll, Nicholas Batt, Rohit Sawhney, Myo J. Tang, John Lubel, Stephen Riordan, Nicholas Hannah, James Haridy, Siddharth Sood, Eileen Lam, Elysia Greenhill, Ammar Majeed, William Kemp, John Zalcberg and Stuart K. Robertsadd Show full author list remove Hide full author list
Cancers 2023, 15(24), 5741; https://doi.org/10.3390/cancers15245741 - 7 Dec 2023
Viewed by 1167
Abstract
The optimal treatment approach in very-early and early-stage hepatocellular carcinoma (HCC) is not precisely defined, and there is ambiguity in the literature around the comparative efficacy of surgical resection versus ablation as curative therapies for limited disease. We performed this real-world propensity-matched, multi-centre [...] Read more.
The optimal treatment approach in very-early and early-stage hepatocellular carcinoma (HCC) is not precisely defined, and there is ambiguity in the literature around the comparative efficacy of surgical resection versus ablation as curative therapies for limited disease. We performed this real-world propensity-matched, multi-centre cohort study to assess for differences in survival outcomes between those undergoing resection and those receiving ablation. Patients with Barcelona Clinic Liver Cancer (BCLC) 0/A HCC first diagnosed between 1 January 2016 and 31 December 2020 who received ablation or resection as initial treatment were included in the study. A total of 450 patients were included in the study from 10 major liver centres including two transplant centres. Following propensity score matching using key covariates, 156 patients were available for analysis with 78 in each group. Patients who underwent resection had significantly improved overall survival (log-rank test p = 0.023) and local recurrence-free survival (log rank test p = 0.027) compared to those who received ablation. Based on real-world data, our study supports the use of surgical resection in preference to ablation as first-line curative therapy in appropriately selected BCLC 0/A HCC patients. Full article
(This article belongs to the Special Issue Insights and Advances in the Surgical Management of Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Review

Jump to: Research

13 pages, 936 KiB  
Review
Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma
by Sami Fares, Chase J. Wehrle, Hanna Hong, Keyue Sun, Chunbao Jiao, Mingyi Zhang, Abby Gross, Erlind Allkushi, Melis Uysal, Suneel Kamath, Wen Wee Ma, Jamak Modaresi Esfeh, Maureen Whitsett Linganna, Mazhar Khalil, Alejandro Pita, Jaekeun Kim, R. Matthew Walsh, Charles Miller, Koji Hashimoto, Andrea Schlegel, David Choon Hyuck Kwon and Federico Aucejoadd Show full author list remove Hide full author list
Cancers 2024, 16(8), 1453; https://doi.org/10.3390/cancers16081453 - 10 Apr 2024
Viewed by 1656
Abstract
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize [...] Read more.
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death and the sixth most diagnosed malignancy worldwide. Serum alpha-fetoprotein (AFP) is the traditional, ubiquitous biomarker for HCC. However, there has been an increasing call for the use of multiple biomarkers to optimize care for these patients. AFP, AFP-L3, and prothrombin induced by vitamin K absence II (DCP) have described clinical utility for HCC, but unfortunately, they also have well established and significant limitations. Circulating tumor DNA (ctDNA), genomic glycosylation, and even totally non-invasive salivary metabolomics and/or micro-RNAS demonstrate great promise for early detection and long-term surveillance, but still require large-scale prospective validation to definitively validate their clinical validity. This review aims to provide an update on clinically available and emerging biomarkers for HCC, focusing on their respective clinical strengths and weaknesses. Full article
(This article belongs to the Special Issue Insights and Advances in the Surgical Management of Hepatocellular Carcinoma)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop